3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Warts
1
Virus Diseases
1
Skin Diseases, Viral
1
Skin Diseases, Infectious
1
Skin Diseases
1
Sexually Transmitted Diseases, Viral
1
Sexually Transmitted Diseases
1
Papillomavirus Infections
1
Condylomata Acuminata
1
Interventions
human papillomavirus vaccine, L1 type 16, 18
35
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
23
Papillomavirus Vaccines
14
Data Collection
7
Blood Specimen Collection
7
Vaccines
6
Vaccines, Synthetic
5
Educational Status
5
Radiotherapy, Intensity-Modulated
4
Human Papillomavirus Recombinant Vaccine nonavalent
4
Early Intervention, Educational
4
Vaginal Smears
3
Surveys and Questionnaires
3
Polymerase Chain Reaction
3
Paclitaxel
3
Methods
3
Engerix-B
3
Colposcopy
3
Cisplatin
3
halofantrine
2
fludarabine phosphate
2
fludarabine
2
aldesleukin
2
Watchful Waiting
2
Taxes
2
Patient Navigation
2
Papanicolaou Test
2
Observation
2
Light Coagulation
2
Imiquimod
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Papillomavirus Infections
×
VP-102
×
Clear all
NCT03981822
2024-11-27
CARE-1
Verrica Pharmaceuticals Inc.
Phase 2
Completed
105 enrolled
24 charts